Atlas Trials

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

Clinical trial NCT06331624 · COMPLETED

Trial details

NCT number
NCT06331624
Sponsor
GRI Bio Operations, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Idiopathic Pulmonary FibrosisIPF
Start date
2024-04-24
Primary completion
2025-09-30
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.